Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
IPO Year: 2020
Exchange: NASDAQ
Website: outsetmedical.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/8/2024 | $6.00 → $3.00 | Outperform → Sector Perform | RBC Capital Mkts |
6/21/2024 | $5.00 → $6.00 | Sector Perform → Outperform | RBC Capital Mkts |
4/8/2024 | $6.00 | Buy | BTIG Research |
4/5/2024 | $6.00 | Neutral → Buy | CL King |
1/12/2024 | $14.00 → $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
10/13/2023 | $32.00 → $3.00 | Buy → Underperform | BofA Securities |
8/17/2023 | Neutral | CL King | |
11/11/2022 | $23.00 | Outperform | RBC Capital Mkts |
7/14/2022 | $48.00 → $20.00 | Overweight → Equal-Weight | Morgan Stanley |
3/2/2022 | $50.00 | Buy | BofA Securities |
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Oppenheimer analyst Brian Nagel upgraded the rating for NIKE, Inc. (NYSE:NKE) from Perform to Outperform, while raising the price target from $110 to $120. Nike shares gained 0.8% to close at $95.57 on Thursday. See how other analysts view this stock. Morgan Stanley analyst Carlos De Alba upgraded Alcoa Corporation (NYSE:AA) from Equal-Weight to Overweight and boosted the price target from $36.5 to $50. Alcoa shares gained 4% to close at $38.98 on Thursday. See how other analysts view
RBC Capital analyst Shagun Singh upgrades Outset Medical (NASDAQ:OM) from Sector Perform to Outperform and raises the price target from $5 to $6.
The MANTRA (CRYPTO: OM) token has experienced a significant surge in the last 24 hours, with its value rising to $1.07. This spike follows a recent development involving a partnership with a bank in the UAE. What Happened: MANTRA surged by 18.58% following a recent agreement between Zand Bank and MANTRA, signing a Memorandum of Understanding for real-world asset compliance in the UAE. Under this MOU, MANTRA and Zand Bank are set to collaborate closely to establish clear frameworks for RWA tokenization, ensuring compliance with the Virtual Asset Regulatory Authority of Dubai. This strategic move aims to facilitate seamless tokenization of real-world assets within the UAE, enhancing the
Outset Medical (NASDAQ:OM) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.55) by 3.64 percent. This is a 20.83 percent increase over losses of $(0.72) per share from the same period last year. The company reported quarterly sales of $28.168 million which missed the analyst consensus estimate of $30.341 million by 7.16 percent. This is a 15.83 percent decrease over sales of $33.467 million the same period last year.
Gainers CytomX Therapeutics (NASDAQ:CTMX) stock increased by 87.1% to $7.84 during Wednesday's after-market session. The market value of their outstanding shares is at $534.1 million. As per the press release, Q1 earnings came out today. ZimVie (NASDAQ:ZIMV) shares increased by 17.03% to $18.0. The company's market cap stands at $489.9 million. The company's, Q1 earnings came out today. Aesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 15.0% to $0.53. The market value of their outstanding shares is at $25.2 million. electroCore (NASDAQ:ECOR) shares rose 11.98% to $7.85. The market value of their outstanding shares is at $47.1 million. The company's, Q1 earnings came out today.
Outset Medical, Inc. (NASDAQ:OM) shares are trading higher Monday after the company announced that TabloCart with prefiltration received FDA clearance. The Details: Outset said that it has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the United States. “With the FDA’s clearance of TabloCart with prefiltration, we have delivered features to the Tablo Hemodialysis System that increase the flexibility for nurses and health systems to serve patients from the ICU to the bedside,” said Leslie Trigg, CEO of Outset Medical. “Today’s announcement underscores Outset Medical’s commitment to innovation and our ongoing dedication to trans
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 35.61% to $1.98. The company's market cap stands at $6.3 million. Outset Medical (NASDAQ:OM) stock rose 26.15% to $3.96. The company's market cap stands at $204.8 million. Nanoviricides (AMEX:NNVC) stock moved upwards by 25.66% to $1.42. The market value of their outstanding shares is at $16.7 million. Chemomab Therapeutics (NASDAQ:CMMB) stock rose 22.16% to $0.9. The market value of their outstanding shares is at $12.8 million. Titan Pharma (NASDAQ:TTNP) shares moved u
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. "Dale brings more than 30 years of experience in building diverse and dynamic teams to Outset at a time of exceptional growth for our team," said Chair and CEO Leslie Trigg. "He leads with purpose and deeply understands the role values and culture play in building high-performance organizations, critical traits as we focus on transforming dialysis." Mr. Jones is a Senior Advisor at Diversified Search Group, and previously served as its CEO for more than eight years. He began his career in banking
Renowned MedTech leaders join EBR Board of Directors Highlights: Dr Evans, Dr Steinhaus and Ms Drexler to join EBR Systems' Board ahead of the planned A$110m IPO on the Australian Stock Exchange Board appointments follow the retirement of Mr Dave Stassen and Dr Leighton Read New EBR Systems' Board consists of Mr Allan Will, Mr John McCutcheon, Dr Christopher Nave, Mr Trevor Moody, Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced the appointment of Dr Bronwyn Evans, Dr David Steinhaus and Ms Karen Drexler to the Board as Independent Non-Executive Directors. D
Holly Sheffield, Medical Technology Executive and Investment Banker Hank Plain, Serial Entrepreneur, Executive and Venture Capital Leader James Rogers, Public and Private Medical Technology Investor Imperative Care, Inc. today announced three appointments to the company's Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers. "We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts," said Fred Khosravi, Chairman and CEO of Imperative Care. "Having these high-caliber professionals join our Boar
Reports Preliminary Results for Second Quarter 2021 Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Rebecca Chambers will step down from her position as Chief Financial Officer to pursue other opportunities, effective July 16, 2021. Nabeel Ahmed, current Vice President, Finance, has been named Interim Chief Financial Officer effective upon Ms. Chambers' departure. Outset announced that preliminary unaudited net revenue for the second quarter of 2021 is expected to be in the range of $24.5 million to $25.0 million, representing growth of 109% to 113% over
Former Head of Engineering and Science for Health AI at Amazon Web Services Joins Dialysis Technology Innovation Leader Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a dialysis technology innovator, today announced the appointment of Jean-Olivier Racine as Chief Technology Officer. In this new role, Racine will oversee the strategic advancement of Outset's product technology, amplifying the company's data-driven innovation engine to further elevate the patient care experience and drive operating efficiencies for providers. Racine joins Outset Medical with more than two decades of experience in the technology industry. Prior to joining Outset, he worked as the head of engineering and scienc
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, today announced the appointment of Katie Szyman to its board of directors. Szyman, currently Corporate Vice President and General Manager of Critical Care at Edwards Lifesciences, brings more than 30 years of global medtech leadership experience. With a focus on driving sustainable, high-growth revenue, Szyman has introduced to market patient-focused innovations that also drive cost efficiencies for providers. "Katie's impressive track record of ushering medical device companies through market expansion and high growth is ideally sui
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- Bone Health Technologies, a leading innovator of technologies for improving bone health, announces today the close of its $2.5 million funding round and the appointment of three board members: Karen Drexler, MBA, Nancy Lynch, MD, MBA and Sam Goldberger, MD, MBA. "Our mission is to provide an effective and safe treatment for the more than 40 million Americans with low bone density - this capital and the expertise we are bringing to bear is exactly what we need to complete our pivotal trial and bring this important innovation to market," shared Laura Yecies, CEO of Bone Health Technologies (BHT). "We have been involved with Bone Health Te
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), the medical technology company that pioneered the Tablo Hemodialysis System, a first-of-its-kind device to reduce the cost and complexity of dialysis, is strengthening its consumer focus with the appointment of Andrea Saia to its board of directors. Saia’s background in building iconic global brands will help Outset’s efforts to grow the home dialysis market and empower patients to take better charge of their health. A recognized global business leader, Saia is known for building world-class brands with innovative technologies that reshape industries and improve the health and well-being of consumers.
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind device to reduce the cost and complexity of dialysis, is bolstering its board of directors with the appointment of Karen Drexler. Drexler currently serves on the boards of ResMed (NYSE: RMD), a $31B data-driven sleep and respiratory market leader; VIDA Diagnostics, developer of AI-powered lung intelligence and imaging solutions; and Tivic Health, a bioelectronic medicine company. Named one of Women Inc. magazine’s most influential corporate directors in 2018, Drexler brings to Outset a deep understanding of how to utilize data analytics and mac
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
4 - Outset Medical, Inc. (0001484612) (Issuer)
Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2024. "During the quarter, the number of treatments performed each month on Tablo continued at record levels, as utilization remained high and gross margin materially expanded as it has each quarter for more than 3 years," said Leslie Trigg, Chair and Chief Executive Officer. "These results reflect the strength and differentiation of Tablo and the positive impact it is having on the lives of patients and providers. "At the same time, new co
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, August 7, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, August 7, 2024. Those interested i
Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2024. "With our recent 510(k) clearance for TabloCart with Prefiltration, 12th consecutive quarter of gross margin expansion and strong sales pipeline growth during the quarter, we are well positioned to capitalize on the $11 billion U.S. dialysis market opportunity," said Leslie Trigg, Chair and Chief Executive Officer. "Tablo's uniquely compelling value proposition continues to resonate with acute- and home-care providers, with significant
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 8, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, May 8, 2024. Those interested in liste
Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter, Year-End Results, and Recent Highlights Recorded net revenue of $30.5 million in the fourth quarter, bringing 2023 revenue to $130.4 million, a 13% increase compared to $115.4 million in 2022. Increased gross margin in the fourth quarter by nearly 900 basis points from the prior-year period. Fourth quarter gross margin reached 25.3% (26.7% on a non-GAAP basis) compared to 16.5% (17.1% on a non-GAA
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2023 after the close of trading on Wednesday, February 21, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, February 21, 2024. T
Reiterates Updated 2023 Revenue Guidance of Approximately $130 Million Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the third quarter ended September 30, 2023. Revenue for the third quarter was $30.4 million, a 9% increase over revenue of $27.8 million in the third quarter of 2022, and gross margin was 23.6%, or 25.6% on a non-GAAP basis, compared to 16.4% on a non-GAAP basis in the third quarter of 2022. Total cash, including restricted cash, cash equivalents and short-term investments, was $197 million as of Septemb
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 7, 2023. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Tuesday, November 7, 2023. Those interested in listenin
Conference Call Scheduled for 4:30 p.m. ET Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), today announced preliminary financial results for the third quarter ended Sept. 30, 2023, and provided updated financial guidance for 2023. Preliminary revenue for the third quarter was $30.4 million, a 9% increase over revenue of $27.8 million in the third quarter of 2022. Outset now expects revenue for 2023 to be approximately $130 million. Preliminary gross margin for the third quarter was 23.6%, or 25.6% on a non-GAAP basis, compared to 16.4% on a non-GAAP basis in the third quarter of 2022. Total cash, including restricted cash, cash equivalents and short-term investments, was $
Sequential Revenue Growth of 8%, Ninth Consecutive Quarter of Gross Margin Expansion Announces Shipment Pause of TabloCart with Prefiltration Pending 510(k) Clearance Reiterates 2023 Revenue Range of $144 Million to $150 Million Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Recorded net revenue of $36.0 million in the second quarter, a 44% increase compared to $25.1 million in the second quarter of 2022, and an 8% increase compared to $33.5 million in the
8-K - Outset Medical, Inc. (0001484612) (Filer)
144 - Outset Medical, Inc. (0001484612) (Subject)
10-Q - Outset Medical, Inc. (0001484612) (Filer)
8-K - Outset Medical, Inc. (0001484612) (Filer)
144 - Outset Medical, Inc. (0001484612) (Subject)
8-K - Outset Medical, Inc. (0001484612) (Filer)
SD - Outset Medical, Inc. (0001484612) (Filer)
144 - Outset Medical, Inc. (0001484612) (Subject)
8-K - Outset Medical, Inc. (0001484612) (Filer)
8-K - Outset Medical, Inc. (0001484612) (Filer)
Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2024. "During the quarter, the number of treatments performed each month on Tablo continued at record levels, as utilization remained high and gross margin materially expanded as it has each quarter for more than 3 years," said Leslie Trigg, Chair and Chief Executive Officer. "These results reflect the strength and differentiation of Tablo and the positive impact it is having on the lives of patients and providers. "At the same time, new co
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, August 7, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, August 7, 2024. Those interested i
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the Goldman Sachs 45th annual Healthcare conference on Wednesday, June 12, 2024, at 11:20 a.m. Eastern time. A live and archived webcast of the presentation will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc. Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo® Hemodialysis System, FDA cleared for use from the h
Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2024. "With our recent 510(k) clearance for TabloCart with Prefiltration, 12th consecutive quarter of gross margin expansion and strong sales pipeline growth during the quarter, we are well positioned to capitalize on the $11 billion U.S. dialysis market opportunity," said Leslie Trigg, Chair and Chief Executive Officer. "Tablo's uniquely compelling value proposition continues to resonate with acute- and home-care providers, with significant
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of TabloCartTM with prefiltration, an innovative optional accessory for the Tablo® Hemodialysis System. Outset has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the United States. "With the FDA's clearance of TabloCart with prefiltration, we have delivered features to the Tablo Hemodialysis System that increase the flexibility for nurses and health systems to serve patients from
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate at the BofA Securities Health Care conference on Tuesday, May 14, 2024 at 2:20 p.m. Eastern time/11:20 a.m. Pacific time, and at the RBC Capital Markets Global Health Care conference on Wednesday, May 15, 2024 at 1:35 p.m. Eastern time/10:35 a.m. Pacific time. Live and archived webcasts of each session will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc. Outset is a medical technology
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 8, 2024. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, May 8, 2024. Those interested in liste
Agreement designed to provide patients and caregivers access to innovative home dialysis with the Tablo® Hemodialysis System Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, and U.S. Renal Care, the largest privately held kidney care provider in the United States, announced today a multi-year agreement to help accelerate home hemodialysis in the U.S. Studies show patients with end-stage kidney disease (ESKD) are healthier mentally and physically dialyzing at home, more likely to be employed and maintain more control of their daily activities. Yet, just 3% of the ESKD populat
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced its partnership with the American Nephrology Nurses Association (ANNA) as a member of its new Partnership Advisory Council. This collaboration underscores Outset's dedication to supporting the nephrology nursing community and improving patient care in the realm of kidney disease. Leslie Trigg, Chair and CEO of Outset, shared her thoughts on the partnership: "We enthusiastically support ANNA's goal of empowering and educating nephrology nurses who are essential to delivering high-quality care to patients with kidn
Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its board of directors. Mr. Lang most recently served as Chairman and Chief Executive Officer of Vocera Communications, a global provider of clinical communication and workflow solutions, until its acquisition by Stryker for $3 billion in 2022. "Brent brings a wealth of healthcare expertise to the Outset board, including in growing and scaling software-enabled business models, which is well-aligned with our recurring revenue model," said Leslie Trigg,
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
SC 13G - Outset Medical, Inc. (0001484612) (Subject)
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
SC 13G - Outset Medical, Inc. (0001484612) (Subject)
SC 13G - Outset Medical, Inc. (0001484612) (Subject)
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
SC 13G - Outset Medical, Inc. (0001484612) (Subject)
SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)
RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $3.00 from $6.00 previously
RBC Capital Mkts upgraded Outset Medical from Sector Perform to Outperform and set a new price target of $6.00 from $5.00 previously
BTIG Research initiated coverage of Outset Medical with a rating of Buy and set a new price target of $6.00
CL King upgraded Outset Medical from Neutral to Buy and set a new price target of $6.00
RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $6.00 from $14.00 previously
BofA Securities downgraded Outset Medical from Buy to Underperform and set a new price target of $3.00 from $32.00 previously
CL King initiated coverage of Outset Medical with a rating of Neutral
RBC Capital Mkts initiated coverage of Outset Medical with a rating of Outperform and set a new price target of $23.00
Morgan Stanley downgraded Outset Medical from Overweight to Equal-Weight and set a new price target of $20.00 from $48.00 previously
BofA Securities resumed coverage of Outset Medical with a rating of Buy and set a new price target of $50.00